2022
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.
Hayes D, Herbst R, Myles J, Topalian S, Yohe S, Aronson N, Bellizzi A, Basu Roy U, Bradshaw G, Edwards R, El-Gabry E, Elvin J, Gajewski T, McShane L, Oberley M, Philip R, Rimm D, Rosenbaum J, Rubin E, Schlager L, Sherwood S, Stewart M, Taube J, Thurin M, Vasalos P, Laser J. Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. JCO Precision Oncology 2022, 6: e2200454. PMID: 36446042, PMCID: PMC10530621, DOI: 10.1200/po.22.00454.Peer-Reviewed Original ResearchConceptsICI therapyImmune checkpoint inhibition therapyDeath ligand 1 (PD-L1) expressionMultiple predictive biomarkersTumor biomarker testsCheckpoint inhibition therapyLigand 1 expressionDeath ligand 1Field of oncologyICI benefitPredictive factorsPredictive biomarkersInhibition therapyNeoantigen expressionBiomarker testsHealth insurance organizationsUS FoodDrug AdministrationAmerican PathologistsMedicaid ServicesTherapyBiomarker developmentNational InstituteLigand 1Clinical application
2020
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Archives Of Pathology & Laboratory Medicine 2020, 144: 545-563. PMID: 31928354, DOI: 10.5858/arpa.2019-0904-sa.Peer-Reviewed Original ResearchConceptsClinical Oncology/CollegeProgesterone receptor testingEstrogen receptorBreast cancerEndocrine therapyReceptor testingExpert panelAmerican Pathologists (CAP) guideline updatesClinical practice guideline recommendationsMultidisciplinary international expert panelEndocrine therapy benefitPractice guideline recommendationsBreast cancer guidelinesER-positive cancersInvasive breast cancerFuture breast cancerAmerican SocietyBreast cancer samplesInternational expert panelReporting of casesPgR testingTumor cell nucleiCancer guidelinesGuideline recommendationsGuideline update
2018
Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing
Kim AS, Bartley AN, Bridge JA, Kamel-Reid S, Lazar AJ, Lindeman NI, Long TA, Merker JD, J. AJ, Rimm DL, Rothberg PG, Vasalos P, Moncur JT. Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing. JAMA Oncology 2018, 4: 838-841. PMID: 29242895, PMCID: PMC6145687, DOI: 10.1001/jamaoncol.2017.4021.Peer-Reviewed Original ResearchConceptsLaboratory-developed testsPT responseCompanion diagnosticsClinical laboratory testingKRAS testingOncology CommitteeMAIN OUTCOMEUS FoodDrug AdministrationPractice characteristicsDiagnostic testingTumor contentProficiency testingVariant-specific differencesEGFRBRAFClinical diagnostic testingMajority of laboratoriesKRASAssaysLaboratory testingPerformance of laboratoriesKit manufacturersResponseParticipants
2013
A Prospective, Multi-Institutional Diagnostic Trial to Determine Pathologist Accuracy in Estimation of Percentage of Malignant Cells
Viray H, Li K, Long TA, Vasalos P, Bridge JA, Jennings LJ, Halling KC, Hameed M, Rimm DL. A Prospective, Multi-Institutional Diagnostic Trial to Determine Pathologist Accuracy in Estimation of Percentage of Malignant Cells. Archives Of Pathology & Laboratory Medicine 2013, 137: 1545-9. PMID: 24168492, DOI: 10.5858/arpa.2012-0561-cp.Peer-Reviewed Original ResearchConceptsFalse-negative test resultsMalignant cellsMulti-institutional studyColon tissue specimensCriterion standardPatient careTissue specimensTumor tissueDiagnostic trialPathologists' accuracyGenetic alterationsNuclear countsPathologist estimationEstimation of percentageVisual estimationCurrent studyCellsTesting failuresA Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists Criteria
Schalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P. A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists Criteria. Archives Of Pathology & Laboratory Medicine 2013, 138: 213-9. PMID: 24164555, DOI: 10.5858/arpa.2012-0617-oa.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinomaCohort StudiesConnecticutFemaleHospitals, UniversityHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMammary Glands, HumanMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm ProteinsPractice Guidelines as TopicReceptor, ErbB-2Retrospective StudiesSocieties, MedicalUnited StatesUnited States Food and Drug Administration
1997
Comparison of the costs of fine‐needle aspiration and open surgical biopsy as methods for obtaining a pathologic diagnosis
Rimm D, Stastny J, Rimm E, Ayer S, Frable W. Comparison of the costs of fine‐needle aspiration and open surgical biopsy as methods for obtaining a pathologic diagnosis. Cancer 1997, 81: 51-56. PMID: 9100542, DOI: 10.1002/(sici)1097-0142(19970225)81:1<51::aid-cncr11>3.0.co;2-b.Peer-Reviewed Original Research
1989
OBESITY AND HEREDITY IN THE ETIOLOGY OF NON-INSULIN-DEPENDENT DIABETES MELLITUS IN 32,662 ADULT WHITE WOMEN
MORRIS R, RIMM D, HARTZ A, KALKHOFF R, RIMM A. OBESITY AND HEREDITY IN THE ETIOLOGY OF NON-INSULIN-DEPENDENT DIABETES MELLITUS IN 32,662 ADULT WHITE WOMEN. American Journal Of Epidemiology 1989, 130: 112-121. PMID: 2787103, DOI: 10.1093/oxfordjournals.aje.a115302.Peer-Reviewed Original ResearchConceptsPrevalence of diabetesDependent diabetes mellitusFamily historyOdds ratioDiabetes mellitusIdeal weightWhite womenPresence of diabetesCross-sectional studyOverall odds ratioLevels of obesityNon-InsulinRisk factorsIndependent riskDiabetesAdult white womenObesityHereditary factorsWomenPer centHistory indexMellitusPrevalenceQuestionnaire dataWeight 75